Meningitis, Bacterial

Also known as: Bacterial meningitis / Meningitis due to gram-negative bacteria, unspecified / Meningitis bacterial / Bacterial meningitis NOS / Meningitis bacterial NOS / Meningitis due to unspecified bacterium

DrugDrug NameDrug Description
DB00479AmikacinAmikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A [FDA label]. Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A [A39531]. Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum)[L4680]. M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood [L4680]. Several forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection [F1949]. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment [L4680],[L4681].
DB00415AmpicillinAmpicillin is a semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.
DB01413CefepimeCefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. Cefepime is usually reserved to treat severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.
DB01212CeftriaxoneA broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears.
DB00798GentamicinA complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1a, obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation).
DB00760MeropenemMeropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and [DB12107] and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.
DB00781Polymyxin BPolymyxin B was discovered in the 1940s[A176429]. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes[A176426]. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant[A176426]. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of _Pseudomonas aeruginosa_[FDA Label]. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line[A176429].
DB00684TobramycinAn aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the pseudomonas species. It is a 10% component of the antibiotic complex, nebramycin, produced by the same species.
DrugDrug NameTargetType
DB00479Amikacin30S ribosomal protein S12target
DB00415AmpicillinSerum albumincarrier
DB00415AmpicillinSolute carrier family 22 member 5transporter
DB00415AmpicillinSolute carrier family 15 member 1transporter
DB00415AmpicillinSolute carrier family 15 member 2transporter
DB00415AmpicillinPenicillin-binding protein 2atarget
DB00415AmpicillinPenicillin-binding protein 1btarget
DB00415AmpicillinPenicillin-binding protein 3target
DB00415AmpicillinPenicillin-binding protein 1Atarget
DB00415AmpicillinPenicillin-binding protein 2Btarget
DB00415AmpicillinMonocarboxylate transporter 1transporter
DB00415AmpicillinSolute carrier family 15 member 1target
DB00415AmpicillinSolute carrier family 15 member 2target
DB00415AmpicillinAngiopoietin-1 receptortarget
DB01413CefepimeSolute carrier family 22 member 5transporter
DB01413CefepimeSolute carrier family 15 member 1transporter
DB01413CefepimeSolute carrier family 15 member 2transporter
DB01413CefepimePenicillin-binding protein 2target
DB01413CefepimePeptidoglycan synthase FtsItarget
DB01413CefepimePenicillin-binding protein 3target
DB01413CefepimePenicillin-binding protein 2target
DB01212CeftriaxoneSerum albumincarrier
DB01212CeftriaxoneSolute carrier family 15 member 1transporter
DB01212CeftriaxoneSolute carrier family 15 member 2transporter
DB01212CeftriaxoneSolute carrier family 22 member 6transporter
DB01212CeftriaxoneSolute carrier family 22 member 8transporter
DB01212CeftriaxoneSolute carrier family 22 member 11transporter
DB01212CeftriaxonePenicillin-binding protein 2Btarget
DB01212CeftriaxoneGlutamine synthetaseenzyme
DB01212CeftriaxoneSolute carrier family 22 member 11target
DB01212CeftriaxoneSolute carrier family 22 member 6target
DB01212CeftriaxoneSolute carrier family 22 member 8target
DB01212CeftriaxoneSolute carrier family 15 member 1target
DB00798Gentamicin30S ribosomal protein S12target
DB00798Gentamicin16S rRNAtarget
DB00798GentamicinLow-density lipoprotein receptor-related protein 2target
DB00798GentamicinSolute carrier family 22 member 6transporter
DB00798GentamicinNH(3)-dependent NAD(+) synthetasetarget
DB00798GentamicinDihydrofolate reductasetarget
DB00760MeropenemD-alanyl-D-alanine carboxypeptidase DacBtarget
DB00760MeropenemBeta-lactamase OXA-10enzyme
DB00781Polymyxin BBacterial outer membranetarget
DB00781Polymyxin BSolute carrier family 15 member 2transporter
DB00684Tobramycin30S ribosomal protein S12target
DB00684Tobramycin16S rRNAtarget
DB00684TobramycinAminoglycoside 2'-N-acetyltransferaseenzyme
DrugDrug NamePhaseStatusCount
DB10076Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen3Recruiting1
DB00802AlfentanilNot AvailableRecruiting1
DB00479AmikacinNot AvailableRecruiting1
DB00513Aminocaproic AcidNot AvailableRecruiting1
DB00559BosentanNot AvailableRecruiting1
DB01413CefepimeNot AvailableRecruiting1
DB00369CidofovirNot AvailableRecruiting1
DB00537CiprofloxacinNot AvailableRecruiting1
DB00363ClozapineNot AvailableRecruiting1
DB00828FosfomycinNot AvailableRecruiting1
DB00502HaloperidolNot AvailableRecruiting1
DB00598LabetalolNot AvailableRecruiting1
DB08815LurasidoneNot AvailableRecruiting1
DB00959MethylprednisoloneNot AvailableRecruiting1
DB01618MolindoneNot AvailableRecruiting1
DB00607NafcillinNot AvailableRecruiting1
DB01115NifedipineNot AvailableRecruiting1
DB00497OxycodoneNot AvailableRecruiting1
DB00312PentobarbitalNot AvailableRecruiting1
DB00728RocuroniumNot AvailableRecruiting1
DB00658SevelamerNot AvailableRecruiting1
DB00421SpironolactoneNot AvailableRecruiting1
DB00684TobramycinNot AvailableRecruiting1
DB00302Tranexamic acidNot AvailableRecruiting1
DB00512VancomycinNot AvailableRecruiting1
DB01339VecuroniumNot AvailableRecruiting1
DB00682WarfarinNot AvailableRecruiting1
DB00246ZiprasidoneNot AvailableRecruiting1
DB00425ZolpidemNot AvailableRecruiting1